Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.7776
−$0.0138 · -1.74%
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Regular session
$0.7776
−$0.0138 · -1.74%
Regular session · ET · Market data may be delayed.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Day range
Current $0.7776
52-week range
Current $0.7776
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
47
Mixed
Risk
66
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Day range
Current $0.7776
52-week range
Current $0.7776
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 389K USD | — | — | — |
| Gross profit | — | −389K USD | — | — | — |
| Research and development | 12.61M USD | 28.48M USD | 17.5M USD | 22.53M USD | 17.17M USD |
| Selling, general, and administrative | 13.97M USD | 13.55M USD | 11.66M USD | 12.11M USD | 9.82M USD |
| Operating expenses | 26.58M USD | 41.64M USD | 29.16M USD | 34.64M USD | 26.99M USD |
| Interest income | 520K USD | 1.5M USD | 1.12M USD | 549K USD | 1.28K USD |
| Interest expense | 207K USD | 1.32M USD | 1.45M USD | 1.62M USD | 1.28M USD |
| Depreciation and amortization | 266K USD | 389K USD | 381K USD | 638K USD | 374K USD |
| Operating income | −26.58M USD | −42.03M USD | −29.16M USD | −34.64M USD | −26.99M USD |
| Net income | −26.26M USD | −41.84M USD | −29.49M USD | −35.71M USD | −28.3M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 9, 2025 | 1:13 | — | — |
Stock split | Jun 28, 2021 | 1:15 | — | — |
Stock split | Dec 10, 2018 | 1:15 | — | — |
Effective Apr 9, 2025
1:13
Effective Jun 28, 2021
1:15
Effective Dec 10, 2018
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
